What was the clinical trial for people with immunocompromising conditions about, and what are the main results?
A lay language summary, led by experts from the community is a way to go. RBDCOV Community Advisory Panel members worked together with the principal investigator and representatives from HIPRA to develop this summary for HIPRA-HH4 clinical trial.
This reader-friendly document explains this RBDCOV vaccine trial in accessible terms.
Loading...
Reload document
Open in new tab 
About the RBDCOV Project
The RBDCOV project, which aimed to test a vaccine against COVID-19 in the pediatric population, including adolescents, and in immunocompromised individuals, plays a crucial role in vaccine development.
RBDCOV is one of the projects committed to testing and advancing a new vaccine against COVID-19. For this purpose, companies and institutions from five European countries have joined forces. The project is led by the biotechnological pharmaceutical company HIPRA and involves the participation of centers in Spain (Vall d’Hebron Institut de Recerca, Irsicaixa, Fundación Lucha contra el SIDA (FLS), IDIBAPS, IDIBGI, ASPHALION, Vinces Consulting, Zabala Innovation), the United Kingdom (Veristat International), Italy (Fondazione Penta), Germany/Belgum (European AIDS Treatment Group), and Turkey (Metpharm Arastirma Gelistirme Saglik Danismanlik).
The RBDCOV project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101046118. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.